Axiak-Bechtel Sandra M, Mathew Leanne M, Amorim Juliana R, DeClue Amy E
Comparative Oncology Laboratory, Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.
Comparative Internal Medicine Laboratory, Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.
Vet Med Sci. 2019 Nov;5(4):485-493. doi: 10.1002/vms3.191. Epub 2019 Aug 2.
Current advances in immunotherapy are an exciting area of study in canine osteosarcoma (OSA). The objective of this study was to determine the immune response in dogs with osteosarcoma by measuring stimulated leukocyte production of tumor necrosis factor (TNF), interleukin (IL)-6, IL-10 and TNF and IL-6 to IL-10 ratios.
Whole blood was collected from dogs with osteosarcoma receiving non-steroidal anti-inflammatory drugs (NSAIDs, n = 11), dogs with osteosarcoma not receiving NSAIDs (n = 14) and healthy dogs (n = 5).
No difference in TNF production was found among healthy and OSA dogs regardless of NSAID administration following stimulation with lipopolysaccharide (LPS) (p = .410), lipoteichoic acid (LTA) (p = .693) or PBS (p = .120). Leukocyte IL-6 production was greater in all dogs with OSA after stimulation with LPS (p = .015), LTA (p = .014) and PBS (p = .034) with no difference between OSA dogs receiving NSAIDs and those not. No differences in IL-10 were found among healthy controls and dogs with OSA regardless of NSAID use. There was no difference among groups for LPS-stimulated TNF to IL-10 ratios (p = .407). For LTA-stimulated leukocytes, the TNF to IL-10 ratio was lower in dogs with OSA than in healthy dogs (p = .031) with no difference between OSA NSAID dogs compared to OSA non-NSAID dogs (p = .059). No differences were found in LPS (p = .310)- or LTA (p = .265)-stimulated leukocyte IL-6 to IL-10 production ratios among groups.
Dogs with osteosarcoma have an altered pro- and anti-inflammatory immunologic profile compared to healthy dogs regardless of NSAID use. Further study is indicated to determine the potential prognostic and therapeutic implications of these findings.
免疫疗法的当前进展是犬骨肉瘤（OSA）研究中一个令人兴奋的领域。本研究的目的是通过测量肿瘤坏死因子（TNF）、白细胞介素（IL）-6、IL-10的刺激白细胞产生以及TNF与IL-6对IL-10的比率，来确定骨肉瘤犬的免疫反应。
从接受非甾体抗炎药（NSAIDs，n = 11）的骨肉瘤犬、未接受NSAIDs的骨肉瘤犬（n = 14）和健康犬（n = 5）采集全血。
在用脂多糖（LPS）（p = 0.410）、脂磷壁酸（LTA）（p = 0.693）或磷酸盐缓冲液（PBS）（p = 0.120）刺激后，无论是否给予NSAIDs，健康犬和OSA犬之间的TNF产生均无差异。在用LPS（p = 0.015）、LTA（p = 0.014）和PBS（p = 0.034）刺激后，所有骨肉瘤犬的白细胞IL-6产生均更高，接受NSAIDs的骨肉瘤犬和未接受NSAIDs的骨肉瘤犬之间无差异。无论是否使用NSAIDs，健康对照犬和骨肉瘤犬之间的IL-10均无差异。LPS刺激的TNF与IL-10比率在各组之间无差异（p = 0.407）。对于LTA刺激的白细胞，骨肉瘤犬的TNF与IL-10比率低于健康犬（p = 0.031），接受NSAIDs的骨肉瘤犬与未接受NSAIDs的骨肉瘤犬之间无差异（p = 0.059）。各组之间在LPS（p = 0.310）或LTA（p = 0.265）刺激的白细胞IL-6与IL-10产生比率方面未发现差异。
无论是否使用NSAIDs，与健康犬相比，骨肉瘤犬的促炎和抗炎免疫谱均发生改变。需要进一步研究以确定这些发现的潜在预后和治疗意义。
